American Diabetes Association

Skip to Main Content

Table 1—

Baseline clinical data of 16 type 2 diabetic hypertensive patients without overt nephropathy

	Sex	Age (years)	Known duration of diabetes (years)	BMI (kg/m²)	BP (mmHg)	Retinopathy	Antidiabetic treatment
Subject
1	M	50	9	28	137/92	Nil	2
2	F	63	12	25	148/76	Simplex	3
3	M	52	10	30	152/84	Simplex	4
4	F	56	16	43	151/82	Nil	4
5	F	69	10	38	165/91	Nil	3
6	M	56	6	25	168/91	Nil	3
7	M	55	20	27	141/81	Proliferative	3
8	M	59	21	27	160/82	Simplex	3
9	M	64	16	30	168/90	Simplex	3
10	F	66	4	26	161/90	Nil	3
11	F	60	10	19	169/83	Nil	3
12	M	62	20	27	152/82	Proliferative	2
13	F	56	14	39	152/87	Simplex	3
14	M	62	14	31	163/90	Proliferative	3
15	F	50	20	31	156/71	Simplex	2
16	F	61	19	39	159/83	Nil	3
Mean ± SD		59 ± 6	14 ± 5	30 ± 6	156 ± 10/85 ± 6	—	—

	Sex	Age (years)	Known duration of diabetes (years)	BMI (kg/m²)	BP (mmHg)	Retinopathy	Antidiabetic treatment
Subject
1	M	50	9	28	137/92	Nil	2
2	F	63	12	25	148/76	Simplex	3
3	M	52	10	30	152/84	Simplex	4
4	F	56	16	43	151/82	Nil	4
5	F	69	10	38	165/91	Nil	3
6	M	56	6	25	168/91	Nil	3
7	M	55	20	27	141/81	Proliferative	3
8	M	59	21	27	160/82	Simplex	3
9	M	64	16	30	168/90	Simplex	3
10	F	66	4	26	161/90	Nil	3
11	F	60	10	19	169/83	Nil	3
12	M	62	20	27	152/82	Proliferative	2
13	F	56	14	39	152/87	Simplex	3
14	M	62	14	31	163/90	Proliferative	3
15	F	50	20	31	156/71	Simplex	2
16	F	61	19	39	159/83	Nil	3
Mean ± SD		59 ± 6	14 ± 5	30 ± 6	156 ± 10/85 ± 6	—	—

1, Diet; 2, oral hypoglycemic treatment; 3, insulin treatment; 4, insulin and oral hypoglycemic treatment.